secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001628280-23-026757
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q2 revenue $117.7M (+14% YoY); raises FY revenue guidance to $455-470M
------------------------------------------------------------------------------

- Revenue $117.7M, up 14% YoY; net income $27.5M ($0.25 diluted EPS) vs $27.4M ($0.24) in Q2 2022.
- Raises FY 2023 revenue guidance to $455-470M from $435-455M; cash $363.3M.
- Repurchased 6.6M shares for $145.4M in April 2023.
- Clinical: GRACE Phase 3 enrollment complete; relacorilant NDA submission expected Q2 2024.
- ROSELLA ovarian cancer trial enrollment on track to complete by end of 2023; Phase 2b NASH trial to start Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828023026757/0001628280-23-026757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828023026757/cort-20230802.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-026757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer